These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 22079605)
41. Self-administration of injectable contraceptives. Prabhakaran S Contraception; 2008 May; 77(5):315-7. PubMed ID: 18402845 [TBL] [Abstract][Full Text] [Related]
42. Factors affecting continuation rates of DMPA. Hubacher D; Goco N; Gonzalez B; Taylor D Contraception; 1999 Dec; 60(6):345-51. PubMed ID: 10715369 [TBL] [Abstract][Full Text] [Related]
43. [An introductory clinical trial of three-monthly injectable contraceptive-depot medroxyprogesterone acetate]. Shao Q; Jiang H; Fu W Zhonghua Fu Chan Ke Za Zhi; 1999 Jan; 34(1):36-9. PubMed ID: 11263172 [TBL] [Abstract][Full Text] [Related]
44. Continuation rates among injectable contraceptive users. Westfall JM; Main DS; Barnard L Fam Plann Perspect; 1996; 28(6):275-7. PubMed ID: 8959418 [TBL] [Abstract][Full Text] [Related]
45. Bone mineral density changes over two years in first-time users of depot medroxyprogesterone acetate. Clark MK; Sowers MR; Nichols S; Levy B Fertil Steril; 2004 Dec; 82(6):1580-6. PubMed ID: 15589863 [TBL] [Abstract][Full Text] [Related]
46. Depo-Provera: use of a long-acting progestin injectable contraceptive in Turkish women. Aktun H; Moroy P; Cakmak P; Yalcin HR; Mollamahmutoglu L; Danisman N Contraception; 2005 Jul; 72(1):24-7. PubMed ID: 15964288 [TBL] [Abstract][Full Text] [Related]
47. Adolescent and covert family planning users' experiences self-injecting contraception in Uganda and Malawi: implications for waste disposal of subcutaneous depot medroxyprogesterone acetate. Burke HM; Packer C; Wando L; Wandiembe SP; Muwereza N; Pradhan S; Zingani A; Ngwira B Reprod Health; 2020 Aug; 17(1):117. PubMed ID: 32746860 [TBL] [Abstract][Full Text] [Related]
48. A cross-sectional study of the forearm bone mineral density in long-term current users of the injectable contraceptive depot medroxyprogesterone acetate. Viola AS; Castro S; Bahamondes MV; Fernandes A; Viola CF; Bahamondes L Contraception; 2011 Nov; 84(5):e31-7. PubMed ID: 22018135 [TBL] [Abstract][Full Text] [Related]
49. Home-based administration of Sayana® Press: review and assessment of needs in low-resource settings. Keith B; Wood S; Tifft S; Hutchings J Contraception; 2014 May; 89(5):344-51. PubMed ID: 24813924 [TBL] [Abstract][Full Text] [Related]
50. New aspects of injectable contraception. Phillips OP Int J Fertil Womens Med; 2001; 46(1):31-6. PubMed ID: 11294618 [TBL] [Abstract][Full Text] [Related]
51. Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians. Kaunitz AM Int J Fertil Womens Med; 1998; 43(2):73-83. PubMed ID: 9609206 [TBL] [Abstract][Full Text] [Related]
53. Current concepts regarding use of DMPA. Kaunitz AM J Reprod Med; 2002 Sep; 47(9 Suppl):785-9. PubMed ID: 12380407 [TBL] [Abstract][Full Text] [Related]
54. Perceptions of home and self-injection of Sayana® Press in Ethiopia: a qualitative study. Keith B; Wood S; Chapman C; Alemu E Contraception; 2014 May; 89(5):379-84. PubMed ID: 24529492 [TBL] [Abstract][Full Text] [Related]
55. Society of Family Planning committee consensus on self-administration of subcutaneous depot medroxyprogesterone acetate (DMPA-SC). Kohn JE; Berlan ED; Tang JH; Beasley A Contraception; 2022 Aug; 112():11-13. PubMed ID: 35378085 [TBL] [Abstract][Full Text] [Related]
56. Vaginal discharge: a perceived side effect and minor reason for discontinuation in hormonal injectable users in South Africa. Beksinska ME; Rees HV Afr J Reprod Health; 2001 Dec; 5(3):84-8. PubMed ID: 12471932 [TBL] [Abstract][Full Text] [Related]